Plozalizumab(TD-HW392016) is a research-grade recombinant antibody targetingCD192. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CCR2, CC-CKR-2, C-C chemokine receptor type 2, CCR-2, C-C CKR-2, MCP-1-R, CMKBR2, CD192, Monocyte chemoattractant protein 1 receptor
Endotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P41597
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
MLN-1202, anti-CCR2, hu1D9, 1610761-46-0
Background
Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research.
Caption
SDS-PAGE for Research Grade Plozalizumab.
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询